Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
5.45 ^USD	-5.05%		-9.02%	-39.38%

Apr. 24	EU Grants Conditional Marketing Approval for CSL Vifor, Travere’s Kidney Disease Treatment	MT
Apr. 24	Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization	MT

Travere Therapeutics : Material Event (Form 8-K)

September 17, 2021 at 06:12 am EDT


		TRAVERE THERAPEUTICS, INC.

Dated: September 17, 2021		By:	/s/ Elizabeth E. Reed
				Name:	Elizabeth E. Reed
Title:	Senior Vice President, General Counsel and Secretary

Attachments

Original document
Permalink

Disclaimer

Travere Therapeutics Inc. published this content on 17 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 September 2021 10:11:07 UTC.

Latest news about Travere Therapeutics, Inc.

EU Grants Conditional Marketing Approval for CSL Vifor, Travere’s Kidney Disease Treatment	Apr. 24	MT
Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization	Apr. 24	MT
CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy	Apr. 24	CI
Travere Therapeutics to Present Abstracts on Filspari® in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association	Apr. 03	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
Transcript : Travere Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:05 PM	Mar. 12
Travere Therapeutics Files Supplemental New Drug Application for Filspari to Treat IgA nephropathy	Mar. 11	MT
Travere Therapeutics, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration Seeking Full Approval of FILSPARI for Treatment of IgA Nephropathy	Mar. 11	CI
Travere Therapeutics Says EMA Committee Recommends Approval of Sparsentan to Treat Kidney Disease	Feb. 23	MT
Travere Therapeutics, Inc. and Csl Vifor Announce Sparsentan Receives Positive Chmp Opinion for the Treatment of Iga Nephropathy	Feb. 23	CI
Travere drug for rare kidney condition recommended for EU approval	Feb. 23	RE
Transcript : Travere Therapeutics, Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q4 Revenue $45.1M, vs. Street Est of $41.8M	Feb. 15	MT
Travere Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
Wedbush Lifts Travere Therapeutics' Price Target to $13 From $12, Keeps Outperform Rating	Jan. 29	MT
Sector Update: Health Care Stocks Mixed Premarket Friday	Jan. 26	MT
Travere Therapeutics Signs Licensing Agreement With Renalys Pharma for Rare Kidney Disease Therapy	Jan. 26	MT
Travere Therapeutics, Inc. Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations	Jan. 25	CI
Transcript : Travere Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 03:45 PM	Jan. 09
Travere Therapeutics Expects $40 Million in Q4 Net Product Sales	Jan. 08	MT
Travere Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023	Jan. 08	CI
Travere Therapeutics, Inc. Announces Program Updates and Anticipated 2024 Milestones	Jan. 08	CI
Stifel Adjusts Price Target on Travere Therapeutics to $10 From $8, Maintains Hold Rating	Dec. 18	MT
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria	Dec. 14	CI
North American Morning Briefing : Stock Futures -2-	Dec. 06	DJ

Chart Travere Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Companyâs Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Travere Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.45 USD

Average target price

14.79 USD

Spread / Average Target

+171.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TRAVERE THERAPEUTICS, INC.	-39.38%	415M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.86%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.49%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs